At Tyson Eye, we’re committed to pushing the boundaries of what’s possible in eye care, especially when it comes to preserving vision in the face of challenging conditions like Dry Age-Related Macular Degeneration (Dry AMD). If you’ve followed our blog before, you already know we’ve introduced the Valeda Light Delivery System as a promising treatment option for patients with early to intermediate Dry AMD. Now, we’d like to dive deeper into why this innovative therapy is such a game-changer—and why Tyson Eye continues to be a leader in bringing tomorrow’s technology to today’s patients.
What Makes Valeda Different?
Unlike traditional methods that focus primarily on monitoring the progression of Dry AMD, Valeda is designed to actively slow its course. This non-invasive treatment uses Multiwavelength Photobiomodulation (PBM) to stimulate cellular activity and support the health of retinal tissue.
Patients receive a series of short, painless light therapy sessions using specific wavelengths of light red, near-infrared, and yellow—delivered in a way that targets key cells in the eye that are impacted by Dry AMD. Over time, this light therapy helps to improve mitochondrial function, reduces oxidative stress, and potentially preserves vision.
Why Tyson Eye?
Tyson Eye is proud to be one of the first practices in the region to offer Valeda treatments, and our retina specialists are uniquely qualified to oversee these new treatments. Our commitment to staying at the forefront of ophthalmic technology is driven by one goal: protecting your vision with the most effective tools available.
We don’t just invest in the latest devices—we invest in the training, research, and clinical insight necessary to ensure our patients get the best outcomes. When you choose Tyson Eye for your AMD care, you’re partnering with a team that’s passionate about innovation and dedicated to your long-term eye health.
A Growing Need for Early Intervention
As we continue to see an increase in Dry AMD diagnoses—especially among patients over the age of 50—it’s more important than ever to identify and treat the condition in its earliest stages. While there is still no cure for Dry AMD, technologies like Valeda offer new hope for slowing progression before significant vision loss occurs.
If you or a loved one has been diagnosed with Dry AMD, or if you’re noticing subtle changes in your central vision, it’s time to have a conversation with our retina specialists. Early detection combined with advanced therapy can make a real difference.
Experience the Future of Eye Care at Tyson Eye
Dry AMD doesn’t have to mean sitting back and waiting for symptoms to worsen. With the Valeda Light Delivery System, we now have a proactive, non-invasive option that fits seamlessly into your care plan—and Tyson Eye is proud to be one of the few practices bringing this technology to our community.
Let’s keep your vision strong—today and into the future.
Meet our Retina Team
Dr. Marilyn A. Márquez is a fellowship trained ophthalmologist certified by the International Council of Ophthalmology. Dr. Márquez is a retina specialist with training at Duke Eye Center and Bascom Palmer Eye Institute.
Dr. Roman O. Pravak is a board-certified Ophthalmologist and a Retina Specialist, specializing in the medical and surgical treatment of disorders and diseases of the retina and vitreous.
Schedule a consultation with Tyson Eye to find out if Valeda is right for you.
